Cargando…

COVID-19 vaccination challenges: A mini-review

The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohseni Afshar, Zeinab, Barary, Mohammad, Hosseinzadeh, Rezvan, Karim, Bardia, Ebrahimpour, Soheil, Nazary, Kosar, Sio, Terence T., Sullman, Mark J. M., Carson-Chahhoud, Kristin, Moudi, Emaduddin, Babazadeh, Arefeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302531/
https://www.ncbi.nlm.nih.gov/pubmed/35512088
http://dx.doi.org/10.1080/21645515.2022.2066425
_version_ 1784751651472539648
author Mohseni Afshar, Zeinab
Barary, Mohammad
Hosseinzadeh, Rezvan
Karim, Bardia
Ebrahimpour, Soheil
Nazary, Kosar
Sio, Terence T.
Sullman, Mark J. M.
Carson-Chahhoud, Kristin
Moudi, Emaduddin
Babazadeh, Arefeh
author_facet Mohseni Afshar, Zeinab
Barary, Mohammad
Hosseinzadeh, Rezvan
Karim, Bardia
Ebrahimpour, Soheil
Nazary, Kosar
Sio, Terence T.
Sullman, Mark J. M.
Carson-Chahhoud, Kristin
Moudi, Emaduddin
Babazadeh, Arefeh
author_sort Mohseni Afshar, Zeinab
collection PubMed
description The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses.
format Online
Article
Text
id pubmed-9302531
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-93025312022-07-22 COVID-19 vaccination challenges: A mini-review Mohseni Afshar, Zeinab Barary, Mohammad Hosseinzadeh, Rezvan Karim, Bardia Ebrahimpour, Soheil Nazary, Kosar Sio, Terence T. Sullman, Mark J. M. Carson-Chahhoud, Kristin Moudi, Emaduddin Babazadeh, Arefeh Hum Vaccin Immunother Coronavirus – Mini-Review The emergence of SARS-CoV-2 has led to the infection of many people across the globe, over six million deaths, and has placed an unprecedented burden on public health worldwide. The pandemic has led to the high-speed development and production of vaccines against the COVID-19, as vaccines can end the pandemic. At the beginning of the program, vaccinations were initially targeted only at high-risk groups, such as the elderly, those with comorbidities, or healthcare workers. Although most of the mentioned populations have received the two recommended doses, limited resources have left many authorities with an effective vaccine undersupply. Therefore, policies have been implemented to manage the available doses of the vaccines more efficiently. As there is no universally agreed consensus on this topic, we discuss the different recommendations and guidelines regarding the time interval between the two vaccine doses and explain the different scenarios for applying the two doses. Taylor & Francis 2022-05-05 /pmc/articles/PMC9302531/ /pubmed/35512088 http://dx.doi.org/10.1080/21645515.2022.2066425 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Coronavirus – Mini-Review
Mohseni Afshar, Zeinab
Barary, Mohammad
Hosseinzadeh, Rezvan
Karim, Bardia
Ebrahimpour, Soheil
Nazary, Kosar
Sio, Terence T.
Sullman, Mark J. M.
Carson-Chahhoud, Kristin
Moudi, Emaduddin
Babazadeh, Arefeh
COVID-19 vaccination challenges: A mini-review
title COVID-19 vaccination challenges: A mini-review
title_full COVID-19 vaccination challenges: A mini-review
title_fullStr COVID-19 vaccination challenges: A mini-review
title_full_unstemmed COVID-19 vaccination challenges: A mini-review
title_short COVID-19 vaccination challenges: A mini-review
title_sort covid-19 vaccination challenges: a mini-review
topic Coronavirus – Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302531/
https://www.ncbi.nlm.nih.gov/pubmed/35512088
http://dx.doi.org/10.1080/21645515.2022.2066425
work_keys_str_mv AT mohseniafsharzeinab covid19vaccinationchallengesaminireview
AT bararymohammad covid19vaccinationchallengesaminireview
AT hosseinzadehrezvan covid19vaccinationchallengesaminireview
AT karimbardia covid19vaccinationchallengesaminireview
AT ebrahimpoursoheil covid19vaccinationchallengesaminireview
AT nazarykosar covid19vaccinationchallengesaminireview
AT sioterencet covid19vaccinationchallengesaminireview
AT sullmanmarkjm covid19vaccinationchallengesaminireview
AT carsonchahhoudkristin covid19vaccinationchallengesaminireview
AT moudiemaduddin covid19vaccinationchallengesaminireview
AT babazadeharefeh covid19vaccinationchallengesaminireview